Press

Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer

Aug 11 • 4 min read

Apex Labs Ltd., a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces the addition of two new executives to the c-suite, psychiatrist Dr. Mark Johnston, MD, FRCPC, as Chief Medical Officer and Greg Rutherford as Chief Commercial Officer. Dr. Johnston, APEX CMO has been practicing psychiatry for over 20 years running…

Optimi Health Announces CAD $3,000,000 Senior Debt Financing

Aug 11 • 4 min read

Optimi Health Corp. (CSE: OPTI / OTCQX: OPTHF / FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce the non-dilutive Debt Financing Agreement (“DFA”) and General Security Agreement (“GSA”) for proceeds of up to CAD…

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Aug 11 • 10 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 financial results and provided corporate updates. “We continue to focus on our vision to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Looking ahead to the second half of…

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Aug 11 • 3 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™, a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and…

Enthea Reports Clinical Results from First Year of Psychedelic Healthcare Benefit for Employees of Leading California-Based Soap Company

Aug 11 • 5 min read

Enthea, the first and only licensed provider of health insurance benefits to cover psychedelic-assisted therapies, today released their one-year results from the benefit program it administers for Dr. Bronner’s, the seventy-five year old, top-selling natural brand of soap in the United States. The California based company generated $170.3M in revenue in 2023 and prides itself on offering generous employee benefits….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441